This research presents a novel approach to treating autoimmune diseases through the development of Antibody-Drug Conjugates (ADCs) targeting the RORγt pathway. By leveraging computational drug design and molecular docking simulations, we demonstrate that ADC-based precision targeting can selectively bind to RORγt receptors on disease-causing Th17 cells.
Traditional immunosuppressive therapies for conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease lack specificity, causing widespread side effects. Our ADC design offers a paradigm shift toward precision medicine, preserving healthy immune function while directly targeting pathogenic cell populations.